<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recent evidence from the United Kingdom Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study convincingly demonstrates that good glycaemic control is difficult to achieve and, despite its positive impact on microvascular complications, is not sufficient to reduce the risk of <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e> (CHD) </plain></SENT>
<SENT sid="1" pm="."><plain>Syndrome X--a cluster of abnormalities associated with resistance to insulin-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake that have been implicated in accelerating atherogenesis--provides a useful clinical concept to prevent CHD in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Components of syndrome X can include <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, and a procoagulant state, changes that contribute to the development of <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="1" ids="47774">Low-density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) levels are usually close to <z:mpath ids='MPATH_458'>normal</z:mpath>, but the <z:chebi fb="0" ids="47774">LDL-C</z:chebi> is present in abnormally small and dense particles </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="17855">Triglyceride</z:chebi> levels are elevated and are associated with an increase in postprandial accumulation of atherogenic, remnant <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> particles </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="1" ids="47775">High-density lipoprotein cholesterol</z:chebi> levels are typically low </plain></SENT>
<SENT sid="6" pm="."><plain>This particular <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, along with <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e>, induces expression of plasminogen activator inhibitor-1, contributing to a prothrombotic state </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, plaque formation may be accelerated in insulin-resistant subjects by increased expression of <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules on endothelial cells and increased rate of monocyte <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to cultured endothelial cells </plain></SENT>
<SENT sid="8" pm="."><plain>Syndrome X and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are associated with multiple abnormalities that enhance the atherosclerotic process </plain></SENT>
<SENT sid="9" pm="."><plain>The opportunities for new therapeutic approaches to reduce cardiovascular risk will undoubtedly evolve along with our understanding of the complex factors responsible for <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, compensatory <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e>, and CHD </plain></SENT>
</text></document>